Briumvi’s New Subcutaneous Formulation Boosts TG Therapeutics Stock
TG Therapeutics stock rose after early trial results showed its under-skin MS drug worked well and may allow at-home dosing.
/ 2 items
TG Therapeutics stock rose after early trial results showed its under-skin MS drug worked well and may allow at-home dosing.
TG Therapeutics (TGTX) boosts 2025 revenue forecast to $616M on strong Briumvi MS drug sales, projects $875M-$900M for 2026, exceeding Wall Street expectations.